Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, FL 32224, USA.
Mol Neurodegener. 2014 Mar 10;9:11. doi: 10.1186/1750-1326-9-11.
Recent genome-wide association studies (GWAS) of late-onset Alzheimer's disease (LOAD) have identified single nucleotide polymorphisms (SNPs) which show significant association at the well-known APOE locus and at nineteen additional loci. Among the functional, disease-associated variants at these loci, missense variants are particularly important because they can be readily investigated in model systems to search for novel therapeutic targets. It is now possible to perform a low-cost search for these "actionable" variants by genotyping the missense variants at known LOAD loci already cataloged on the Exome Variant Server (EVS). In this proof-of-principle study designed to explore the efficacy of this approach, we analyzed three rare EVS variants in APOE, p.L28P, p.R145C and p.V236E, in our case control series of 9114 subjects. p.R145C proved to be too rare to analyze effectively. The minor allele of p.L28P, which was in complete linkage disequilibrium (D' = 1) with the far more common APOE ϵ4 allele, showed no association with LOAD (P = 0.75) independent of the APOE ϵ4 allele. p.V236E was significantly associated with a marked reduction in risk of LOAD (P = 7.5 × 10⁻⁰⁵; OR = 0.10, 0.03 to 0.45). The minor allele of p.V236E, which was in complete linkage disequilibrium (D' = 1) with the common APOE ϵ3 allele, identifies a novel LOAD-associated haplotype (APOE ϵ3b) which is associated with decreased risk of LOAD independent of the more abundant APOE ϵ2, ϵ3 and ϵ4 haplotypes. Follow-up studies will be important to confirm the significance of this association and to better define its odds ratio. The ApoE p.V236E substitution is the first disease-associated change located in the lipid-binding, C-terminal domain of the protein. Thus our study (i) identifies a novel APOE missense variant which may profitably be studied to better understand how ApoE function may be modified to reduce risk of LOAD and (ii) indicates that analysis of protein-altering variants cataloged on the EVS can be a cost-effective way to identify actionable functional variants at recently discovered LOAD loci.
最近的全基因组关联研究(GWAS)发现,晚发性阿尔茨海默病(LOAD)的单核苷酸多态性(SNP)在众所周知的 APOE 基因座和另外 19 个基因座上存在显著关联。在这些基因座上的功能、与疾病相关的变异中,错义变异尤其重要,因为它们可以在模型系统中进行研究,以寻找新的治疗靶点。现在可以通过对 Exome Variant Server (EVS) 上已经编目的已知 LOAD 基因座上的错义变异进行基因分型,来进行这些“可操作”变异的低成本搜索。在这项旨在探索这种方法疗效的原理验证研究中,我们分析了我们的 9114 名受试者病例对照系列中 APOE 基因上的三个罕见 EVS 变体,p.L28P、p.R145C 和 p.V236E。p.R145C 太罕见,无法有效分析。与更为常见的 APOE ϵ4 等位基因完全连锁不平衡(D' = 1)的 p.L28P 的次要等位基因与 LOAD 无关(P = 0.75),而不考虑 APOE ϵ4 等位基因。p.V236E 与 LOAD 风险显著降低相关(P = 7.5 × 10⁻⁰⁵;OR = 0.10,0.03 至 0.45)。与常见的 APOE ϵ3 等位基因完全连锁不平衡(D' = 1)的 p.V236E 的次要等位基因确定了一个新的与 LOAD 相关的单倍型(APOE ϵ3b),该单倍型与 LOAD 风险降低有关,与更丰富的 APOE ϵ2、ϵ3 和 ϵ4 单倍型无关。后续研究对于证实这种关联的意义并更好地定义其比值比将很重要。载脂蛋白 E p.V236E 取代是第一个位于蛋白质脂质结合、C 端结构域的疾病相关变化。因此,我们的研究 (i) 确定了一种新的 APOE 错义变体,可对其进行研究,以更好地了解 ApoE 功能如何改变以降低 LOAD 的风险,以及 (ii) 表明对 EVS 上编目的改变蛋白质的变异的分析可以是一种具有成本效益的方法,可用于识别最近发现的 LOAD 基因座上的可操作功能变异。